[go: up one dir, main page]

WO2022238745A1 - Composition pharmaceutique topique d'inhibiteurs de hif prolyl hydroxylase - Google Patents

Composition pharmaceutique topique d'inhibiteurs de hif prolyl hydroxylase Download PDF

Info

Publication number
WO2022238745A1
WO2022238745A1 PCT/IB2021/058243 IB2021058243W WO2022238745A1 WO 2022238745 A1 WO2022238745 A1 WO 2022238745A1 IB 2021058243 W IB2021058243 W IB 2021058243W WO 2022238745 A1 WO2022238745 A1 WO 2022238745A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
acid
formula
compound
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/058243
Other languages
English (en)
Inventor
M. E. Kannan
Mukul Jain
Ritu Laddha
Mukesh Ukawala
Jitendra Patel
Jaymeen SHARMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Zydus Lifesciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zydus Lifesciences Ltd filed Critical Zydus Lifesciences Ltd
Publication of WO2022238745A1 publication Critical patent/WO2022238745A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Definitions

  • Present invention relates to topical pharmaceutical composition of HIF prolyl hydroxylase inhibitors or pharmaceutically acceptable salts thereof. Specifically, present invention relates to topical pharmaceutical composition of compound of formula (la) and pharmaceutically acceptable salts thereof. Invention also relates to process for the preparation of topical pharmaceutical composition of compound of formula (la) and pharmaceutically acceptable salts thereof.
  • Hypoxia-inducible factor is a heteroduplex, with a and b subunit.
  • the beta subunit is usually present in excess, while the alpha subunit is the limiting factor in the formation of the functional dimer.
  • the HIF-a subunit binds with the b subunit in the nucleus and, with the cooperation of cofactors, binds to DNA sequences called hypoxia response elements, and hence induces expression of target genes.
  • the activity of HIF is regulated via hydroxylation at two proline residues by an oxygen- sensitive family of prolyl hydroxylase enzymes (PHD), known as PHD1, PHD2 and PHD3.
  • PHD1 oxygen- sensitive family of prolyl hydroxylase enzymes
  • HIF-a subunits are also regulated by hydroxylation at a C-terminal asparagine residue by factor inhibiting HIF (FIH), an oxygen-dependent hydroxylase enzyme.
  • FHI factor inhibiting HIF
  • prolyl hydroxylase inhibitors Some of the prolyl hydroxylase inhibitors have been disclosed in EP661269, W02007070359, W02008076425, WO2011007856, WO2012106472, and WO2013043621.
  • W02004108681 and W02008002576 covers the prolyl hydroxylase inhibitors named Roxadustat and Vadadustat respectively.
  • W02014102818 discloses compounds of the following general formula (I) and US10899713 covers the process for the preparation of these compounds of formula
  • topical administration overcomes the problems associated with oral compositions, use of a topical formulation is beneficial as it avoids first-pass metabolism, circumvents gastrointestinal (“GI”) absorption, can allow delivery of an active ingredient with a relatively short biological half-life, and/or a narrow therapeutic window and facilitates uniform plasma dosing of the active ingredient. Further, there is an unmet need for improved patient compliant topical formulations that are effective in the treatment of skin disorders, and which provide improved delivery of the active agent at the desired site of action, with decreased side effects if any, increased ease of use for the patient, and longer duration of action.
  • GI gastrointestinal
  • present invention relates to topical pharmaceutical composition of HIF prolyl hydroxylase inhibitors or pharmaceutically acceptable salts thereof.
  • present invention relates to a topical pharmaceutical composition comprising HIF prolyl hydroxylase inhibitors or pharmaceutically acceptable salts thereof and one or more suitable pharmaceutically acceptable excipients.
  • present invention provides process for the preparation of topical pharmaceutical composition of prolyl hydroxylase inhibitors or pharmaceutically acceptable salts thereof.
  • present invention relates to topical pharmaceutical composition of compound of formula (la) or its pharmaceutically acceptable salts.
  • present invention relates to a topical pharmaceutical composition
  • a topical pharmaceutical composition comprising compound of formula (la) or its pharmaceutically acceptable salts and one or more suitable pharmaceutically acceptable excipients.
  • present invention relates to process for the preparation of topical pharmaceutical composition of compound of formula (la) or its pharmaceutically acceptable salts.
  • the present invention relates to topical pharmaceutical compositions comprising compound of formula (la) in the form such as lotion, gel, spray, ointment, cream, foam, paste, suspension and solution.
  • the present invention relates to use of topical pharmaceutical composition in skin related disorders.
  • Topical formulation or ‘Topical composition’ means a formulation or composition in which drug may be placed for the direct application to the application to skin surface, hair, nail or mucosal tissues from which an effective amount of drug is released.
  • Treatment means the managing a medical condition of a subject to cure, ameliorate, stabilize or prevent a disease, disorder or a pathological condition.
  • ‘Pharmaceutically acceptable excipient’ or ‘excipient means pharmacologically inactive substances that are added to the preparation of pharmaceutical composition/formulation in addition to the active pharmaceutical ingredient.
  • Term ‘A’ anywhere in specification denotes Maximum individual unknown degradation product.
  • the amount of A should not more than 0.50% by area percentage of HPLC in topical pharmaceutical composition.
  • Term ‘B’ in stability data denotes total degradation product.
  • the amount of B in topical pharmaceutical composition should not more than 2.00% by area percentage of HPLC.
  • Impurity D is the substance (l-(but-3-en-l-yloxy)-4-hydroxy-2-oxo-l,2-dihydroquinoline-3- carbonyl)glycine forms in minor amount during the synthesis of compound of formula (la).
  • the amount of Impurity D in pharmaceutical composition should not be more than 1.00% by area percentage of HPLC.
  • HIF prolyl hydroxylase inhibitors are selected from Roxadustat, Vadadustat, Molidustat and compounds of formula (I) or pharmaceutically acceptable salts thereof.
  • present invention relates to topical pharmaceutical composition of compound of formula (la) or its pharmaceutically acceptable salts.
  • formula (la)
  • pharmaceutically acceptable salts of compound of formula (la) wherein cations for salt are selected from calcium, sodium, potassium, lithium, barium, strontium, magnesium, cesium, copper, cobalt , iron, manganese, lead, aluminum, cadmium , silver, zinc, ammonium, methylamine, dimethylamine, ethylamine, diethyl amine, n-propyl amine, isopropyl amine, diisopropyl amine, N-methyl isopropyl amine, n-butyl amine, t-butyl amine, 2-butamine, 1,2-ethane diamine, N-methylglucamine, N,N,N-trimethyl ethanolamine hydroxide (choline), tromethamine, cyclohexylamine, N-methyl cyclohexylamine, guanidine, N-(4-aminobutyl) guanidine, dicyclohexylamine, benzene-me
  • topical pharmaceutical composition comprising compound of formula (la) in therapeutically effective amount selected from 0.01%w/w to 20.00 % w/w. In one of the preferred embodiment topical pharmaceutical composition comprising compound of formula (la) in therapeutically effective amount selected from 1.00%w/w to 10.00%w/w. In yet another preferred embodiment, topical pharmaceutical composition comprising compound of formula (la) is in amount selected from 1.00%w/w to 5.00%w/w.
  • the present invention provides topical pharmaceutical compositions comprising compound of formula (la) in the form such as lotion, gel, spray, ointment, cream, foam, paste, suspension, solution and the like.
  • present invention provides topical pharmaceutical compositions comprising compound of formula (la) or its pharmaceutically acceptable salts and one or more suitable pharmaceutically acceptable excipients.
  • Suitable pharmaceutically acceptable excipients includes but not limited to Solubilizers/co solvents, permeation enhancers, humectant, antioxidants, preservative, chelating agent, acidifying/alkalizing agents, gelling agents, emollient/ stiffening agent, emulsifying agents, ointment bases.
  • present invention provides topical pharmaceutical composition in gel form comprising compound of formula (la) or its pharmaceutically acceptable salts and suitable pharmaceutically acceptable excipients.
  • compositions for topical gel composition are selected from gelling agent, humectant, chelating agents, permeation enhancers, preservatives, antioxidants, solubilizing agents, acidifying/alkalizing agent and the like.
  • topical gel composition comprising compound of formula (la) in therapeutically effective amount selected from 1.00%w/w to 10.00%w/w.
  • gel composition comprising compound of formula (la) in therapeutically effective amount of 3.00% w/w.
  • composition comprising pharmaceutically acceptable excipients gelling agent of about l.OOto 10.00%w/w, solubilizers or co-solvent of about 0.10 to 30.00%w/w, alkalizing agent of about 0.01 to 10.00%w/w and purified water to adjust the sufficient quantity.
  • topical gel formulation of 3.00%w/w compound of formula (la) further comprising 2.00%w/w hydroxyethyl cellulose, 0.40%w/w sodium hydroxide, 5.00%w/w glycerin and 89.60%w/w purified water to adjust the quantity.
  • present invention provides topical pharmaceutical composition in solution form comprising compound of formula (la) or its pharmaceutically acceptable salts and suitable pharmaceutically acceptable excipients.
  • topical solution composition comprising compound of formula (la) in therapeutically effective amount selected from 0.01%w/w to 10.00 % w/w.
  • topical solution composition comprising compound of formula (la) in therapeutically effective amount is 5.00%w/w.
  • topical solution of compound of formula (la) further comprising alkalizing agent of about 0.01 to 10.00 %w/w; solubilizing agents of about 0.10 to 30.00 %w/w and purified water to adjust the total volume accordingly.
  • topical solution of 5.00%w/w compound of formula (la) comprising 0.62%w/w sodium hydroxide and 5.00%w/w glycerin and 89.38%w/w purified water to adjust the total volume.
  • present invention provides topical pharmaceutical composition in lotion form comprising compound of formula (la) or its pharmaceutically acceptable salts and suitable pharmaceutically acceptable excipients.
  • compositions for topical lotion composition are selected from gelling agent, humectant, emulsifying agent, emollient, chelating agents, permeation enhancers, preservatives, antioxidants, solubilizing agents, acidifying/alkalizing agent and the like.
  • topical lotion composition comprising compound of formula (la) in therapeutically effective amount selected from 0.01%w/w to 10.00 % w/w. In a preferred embodiment topical lotion composition comprising compound of formula (la) in therapeutically effective amount selected from 3.00%w/w. In one embodiment, topical lotion of compound of formula (la) further comprising alkalizing agent of about 0.01 to 10.00 %w/w, solubilizing agents of about 0.10 to 30.00 %w/w, gelling agent of about 0.05 to 1.00%w/w and purified water to adjust the sufficient quantity.
  • topical lotion of 3.00% w/w compound of formula (la) further comprising 0.75%w/w hydroxyethyl cellulose, 0.40% w/w sodium hydroxide, 5.00% w/w glycerin and 90.85% w/w of purified water to adjust the quantity.
  • present invention provides topical pharmaceutical composition in cream form comprising compound of formula (la) or its pharmaceutically acceptable salts and suitable pharmaceutically acceptable excipients.
  • compositions for topical cream composition are selected from humectant, emulsifying agent, emollient, chelating agents, permeation enhancers, preservatives, antioxidants, solubilizing agents, acidifying/alkalizing agent and the like.
  • topical cream composition comprising compound of formula (la) in therapeutically effective amount selected from 0.01%w/w to 10.00 % w/w.
  • topical cream composition comprising compound of formula (la) in therapeutically effective amount selected from 1.00%w/w to 5.00%w/w.
  • topical cream composition comprising humectant of about 0.50 to 35.00%w/w, emollient/stiffening agent of about 1.00 to 40.00%w/w, emulsifying agent of about 1.00 to 30.00%w/w, penetration enhancer of about 0.50 to 15.00%w/w, preservatives of about 0.001 to 1.00%w/w, alkalizing agent of about 0.01 to 10.00%w/w and purified water to adjust the quantity.
  • topical cream composition of 1.00 % w/w compound of formula (la) comprises 0.14% w/w sodium hydroxide, 5.00%w/w propylene glycol, 10.00%w/w white soft paraffin, 6.00%w/w liquid paraffin, 7.20%w/w Cetostearyl alcohol, 1.80%w/w Cetomacrogol 1000, 0.05% w/w propyl paraben, 0.10%w/w methyl paraben and 68.71%w/w purified water to adjust the quantity.
  • topical cream composition of 3.00 % w/w compound of formula (la) comprises 0.40% w/w sodium hydroxide, 5.00% w/w propylene glycol, 10.00%w/w white soft paraffin, 6.00%w/w liquid paraffin, 7.20%w/w Cetostearyl alcohol, 1.80%w/w Cetomacrogol 1000, 0.05% w/w propyl paraben, 0.10%w/w methyl paraben and 66.45%w/w purified water to adjust the quantity.
  • topical cream composition of 5.00 % w/w compound of formula (la) comprises 0.62% w/w sodium hydroxide, 5.00% w/w propylene glycol, 10.00%w/w white soft paraffin, 6.00%w/w liquid paraffin, 7.20%w/w Cetostearyl alcohol, 1.80%w/w Cetomacrogol 1000, 0.05% w/w propyl paraben, 0.10%w/w methyl paraben and 64.23%w/w purified water to adjust the quantity.
  • present invention provides topical pharmaceutical composition in ointment form comprising compound of formula (la) or its pharmaceutically acceptable salts and suitable pharmaceutically acceptable excipients.
  • compositions for topical ointment composition are selected from ointment bases, preservatives, solubilizing agents, emollient, emulsifying agent, permeation enhancers, antioxidants and the like.
  • topical ointment composition comprising compound of formula (la) in therapeutically effective amount selected from 0.01%w/w to 10.00 % w/w.
  • topical ointment composition comprising compound of formula (la) in therapeutically effective amount is 1.00 %w/w.
  • topical ointment composition further comprises ointment base of about 2.00 to 99.00%w/w.
  • topical ointment composition of 1.00%w/w compound of formula (la) further comprises 79.00%w/w polyethylene glycol 400 and 20.00%w/w polyethylene glycol 6000.
  • present invention provides topical pharmaceutical composition in foam form comprising compound of formula (la) or its pharmaceutically acceptable salts and suitable pharmaceutically acceptable excipients.
  • compositions for topical foam composition are selected from surfactant/ emulsifying agents, propellants, alkalizing agents, solubilizers/ co-solvents emollient / stiffening agents, ointment base and the like.
  • topical foam composition comprising compound of formula (la) in therapeutically effective amount selected from 0.01%w/w to 10.00 % w/w.
  • topical foam of compound of formula (la) further comprises emollient or stiffening agents of about 0.20 to 10.00%w/w, propellants of about 1.00 to 25.00%w/w, emulsifying agent of about 0.10 to 20.00%w/w, ointment base of about 1.00 to 30.00%w/w, alkalizing agent of about 0.01 to 10.00%w/w, solvents and co-solvents of about 5.00 to 80.00%w/w and purified water to adjust the quantity.
  • emollient or stiffening agents of about 0.20 to 10.00%w/w
  • propellants of about 1.00 to 25.00%w/w
  • emulsifying agent of about 0.10 to 20.00%w/w
  • ointment base of about 1.00 to 30.00%w/w
  • alkalizing agent of about 0.01 to 10.00%w/w
  • solvents and co-solvents of about 5.00 to 80.00%w/w and purified water to adjust the quantity.
  • process for preparation of topical foam comprising following steps: i. Compound of formula (la) is dispersed in a part of Purified water under stirring. ii. Alkalizing agent is dissolved in another portion of Purified water under stirring. iii. Solution of Step (ii) is added to mixture of step (i) under stirring. Stirring is continued till clear solution is obtained. iv. Ointment base, co- solvent and emulsifying agents and remaining amount of purified water are added to solution of step (iii) and mixed under stirring. v. Solution of Step (iv) is heated to 70°C and maintained at same temperature. vi. Emollients are mixed, heated and melted to 70°C and maintained at same temperature. vii.
  • Step (vi) Solution of Step (vi) is added to aqueous solution of step (v) under stirring at 70°C and mixed for 10 min. viii.
  • the resultant emulsion is cooled to 25-30°C and required amount of solvent is added into it under stirring. ix.
  • the final mixture is filled in canister with crimp valve.
  • Propellant is filled in to the canister under pressure and sealed.
  • present invention provides topical pharmaceutical composition in suspension form comprising compound of formula (la) or its pharmaceutically acceptable salts and suitable pharmaceutically acceptable excipients.
  • compositions for topical suspension composition are selected from solubilizing agents/ co-solvent, gelling agents and the like.
  • topical suspension composition comprising compound of formula (la) in therapeutically effective amount selected from 0.01%w/w to 10.00%w/w.
  • topical suspension of compound of formula (la) further comprises solubilizing agents /co-solvents of about 0.10 to 10.00%w/w, gelling agents of about 0.01 to 10.00%w/w and purified water to adjust the quantity.
  • process for preparation of topical suspension comprising following steps: i. Solubilizing agent and gelling agent are dissolved into purified water under stirring. The stirring is continued till clear solution is obtained. ii. Compound of formula (la) is taken in a mortar and approximately 10% percent of suspending vehicle from step I is added to it. This mixture is triturated for 5 minutes continuously. iii. The resultant suspension is completely transferred into a calibrated measuring cylinder and required volume is made up with remaining vehicle from step I. iv. The resultant suspension is mixed for approximately 10 minutes.
  • present invention provides topical pharmaceutical composition in paste form comprising compound of formula (la) or its pharmaceutically acceptable salts and suitable pharmaceutically acceptable excipients.
  • compositions for topical paste composition are selected from gelling agents, ointment bases and the like.
  • topical paste composition comprising compound of formula (la) in therapeutically effective amount selected form 0.01%w/w to 10.00%w/w.
  • topical paste comprising gelling agent of about 20.00 to 80.00%w/w and ointment base of about 1.00 to 30.00%w/w.
  • process for the preparation of topical paste comprising following steps: i. Various Ointment bases are mixed under stirring as required. ii. Compound of formula (la) is added to above mixture under stirring and mixed for 10 minutes. iii. The mixture from step (ii) is added to gelling agent gradually in small amounts and triturated. iv. When addition is completed, the trituration is continued for 15 minutes.
  • Solubilizers/co-solvents used anywhere in the description may be selected from Dimethyl malonate, diethyl succinate, diethyl glutarate, diethyl adipate, dipropyl adipate, dibutyl sebacate, diisopropyl sebacate, diethyl pimelate, diethyl suberate, diethyl azelate, dibutyl adipate, dibutyl sebacate, methyl ethyl succinate, diethyl ethyl-isopropylmalonate, diethyl isosuccinate, benzyl alcohol, benzyl benzoate, cyclodextrin, glycerine monostearate, lecithin, butylene glycol, dibutyl phthalate, diethyl phthalate, dimethyl ether, diethyl ether, ethyl acetate, ethyl lactate, ethyl oleate
  • Permeation enhancers used anywhere in the description may be selected from polyethylene glycol, polyethylene glycol monolaurate, butanediol, dimethylsulfoxide, decylmethylsulfoxide, diethylene glycol monoethyl ether (e.g., Transcutol® P), Cetomacrogol 1000, lauric acid, oleic acid, valeric acid, isopropyl myristate, isopropyl palmitate, methyl propionate, and ethyl oleate; urea, dimethyl acetamide, dimethylformamide 2- pyrrolidone, ethanolamine, methyl-2 -pyrrolidone, diethanolamine, triethanolamine, terpenes, alkanones, salicylic acid, citric acid, succinic acid and suitable mixtures thereof.
  • Humectants used anywhere in the description may be selected from glycerin, propylene glycol, dipropylene glycol, polypropylene glycol, urea, polyglycerine, 1,3-butylene glycol, pantothenol, gluconic acid salts, butane diols, Polyethylene glycol and its derivatives, xylitol sorbitol solution, 1,2,6 -hexanetriol and suitable mixtures thereof.
  • Antioxidants used anywhere in the description may be selected from ascorbic acid (vitamin C), glutathione, lipoic acid, uric acid, carotenes, a-tocopherol (vitamin E), ubiquinol, butylated hydroxyanisole, butylated hydroxytoluene, sodium benzoate, sodium thiosulphate, sodium metabisulphite, propyl gallate (PG, E310), and tertiary-butylhydroquinone, Idebenone, Lycopene and suitable mixtures thereof.
  • Preservatives used anywhere in the description may be selected from Methyl paraben, Propyl paraben, benzoic acid, imidurea, sorbic acid, potassium sorbate, benzalkonium chloride, phenyl mercuric acetate, chlorobutanol, phenoxyethanol, benzyl alcohol, chlorocresol, metacresol, cetrimonium chloride, benzethonium chloride, sodium edetate, boric acid, phenol and suitable mixtures thereof.
  • Chelating agents used anywhere in the description may be selected from EDTA, disodium EDTA, trisodium EDTA, EGTA, disodium EGTA, trisodium EGTA, citric acid, phosphoric acid, succinic acid, and suitable mixtures thereof.
  • Alkalizing agents used anywhere in the description may be selected from trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, meglumine, dicyclohexylamine, N,N'- dibenzylethylenediamine, arginine, lysine, ornithine, sodium bicarbonates, sodium hydroxide, potassium hydroxide and suitable mixtures thereof.
  • Buffers used anywhere in the description may be selected from citrate/citric acid buffers, acetate/acetic acid buffers, phosphate/phosphoric acid buffers, formate/formic acid buffers, propionate/propionic acid buffers, carbonate/carbonic acid buffers, ammonium/ammonia buffers and suitable mixtures thereof.
  • Gelling agents used anywhere in the description may be selected from carbomer, Methyl cellulose, sodium carboxy methyl cellulose, Carrageenan, colloidal silicon dioxide, Guar gum, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxy propyl cellulose, Gelatin, polyethyene oxide, alginic acid, sodium alginate, fumed silica, polyvinylpyrrolidone, polyvinyl alcohol and suitable mixtures thereof.
  • Emollient/ stiffening agents used anywhere in the description may be selected from camauba wax, cetyl alcohol, cetyl ester wax, hydrous lanolin, lanolin, lanolin alcohols, paraffin, white soft paraffin, petrolatum polyethylene glycol, stearic acid, stearyl alcohol, white wax, yellow wax, liquid paraffin, liquid petrolatum, jojoba oil, sesame oil, rapeseed oil, purcellin oil, 2- ethylhexyl palmitate, 2-octyldodecyl stearate, 2-octyldodecyl erucate, isostearyl isostearate, 2- octyldodecyl benzoate, triglycerides of caprylic/capric acids, octyldodecanol, isohexadecane, capmul MCM and suitable mixtures thereof.
  • Emulsifying agents used anywhere in the description may be selected from polysorbate 20, polysorbate 60, polysorbate 80, poloxamer, Cetostearyl alcohol, Polyoxyethylene lauryl alcohol emulsifying wax, sorbitan monostearate, sorbitan monooleate, sodium lauryl sulphate, propylene glycol monostearate, glyceryl monostearate and suitable mixtures thereof.
  • Ointment bases used anywhere in the description may be selected from oleaginous bases such as petrolatum, white/yellow petrolatum, liquid paraffin, hard paraffin, white ointment; absorption bases such as lanolin, anhydrous lanolin, cold cream, etc.; water removable bases: hydrophilic ointments, vanishing creams and water; water soluble bases such as polyethylene glycol 200, 300, 400, 1500, 3000, 6000 and suitable mixtures thereof.
  • oleaginous bases such as petrolatum, white/yellow petrolatum, liquid paraffin, hard paraffin, white ointment
  • absorption bases such as lanolin, anhydrous lanolin, cold cream, etc.
  • water removable bases hydrophilic ointments, vanishing creams and water
  • water soluble bases such as polyethylene glycol 200, 300, 400, 1500, 3000, 6000 and suitable mixtures thereof.
  • Propellants used anywhere in the description may be selected from chlorofluorocarbons and flurocarbons such as chlorodifluoromethane chlorotrifluoromethane, dichlorodifluoromethane, trichlorofluoromethane, tetrafluoroethane, 1,2- dichlorotetrafluoroethane, trichlorofluoroethane, chloropentafluoropropane, chloroheptafluoropropane, heptafluoropropane, perfluorocyclopropane, perfluoropropane, perfluoro-n-butane, perfluoroisobutane, perfluorocyclobutane, perfluorodimethyl ether, perfluorodiethyl ether, perfluorofuran, perfluoromethylamine, bis-(trifluoromethyl)sulfide, and trifluoromethylpentafluorosulfide, alkane
  • Suspending agents used anywhere in the description may be selected from acacia, agar, Alginic acid, bentonite, calcium stearate, carbomer, carboxymethyl cellulose, carrageenan, methyl cellulose, powder cellulose, ceratonia, colloidal silicon dioxide, dextrin, gelatin, guar gum, hectorite, hypromellose, hydroxy propyl cellulose, magnesium silicate, kaolin, maltitol, polycarbophil, polyethylene glycol, potassium alginate, povidone, propylene glycol alginate, saponite, sodium starch glycolate, sucrose, tragacanth, xanthan gum and suitable mixture thereof.
  • topical pharmaceutical composition comprising compound of formula (la) in therapeutically effective amount selected from 0.01%w/w to 20.00 % w/w. In a preferred embodiment topical pharmaceutical composition comprising compound of formula (la) in therapeutically effective amount selected from 1.00%w/w to 10.00%w/w.
  • topical pharmaceutical composition comprising compound of formula (la) wherein relative amount of maximum individual unknown degradation product A to compound of formula (la), should not more than 0.50% by area percentage of HPLC.
  • relative amount of total degradation product B to compound of formula (la) should not more than 2.00% by area percentage of HPLC in topical pharmaceutical composition.
  • relative amount of impurity D to compound of formula (la) should not more than 1.00% by area percentage of HPLC.
  • pH of the topical pharmaceutical composition is selected from the range of 4.0 to 9.0.
  • pH range of topical pharmaceutical composition comprising compound of formula (la) is selected from 6.0 to 8.5.
  • present invention provides process for the preparation of topical pharmaceutical composition of compound of formula (la) or its pharmaceutically acceptable salts as provided in following examples.
  • present invention relates to use in treatment of skin related disorders.
  • topical pharmaceutical composition of compound of formula (la) is useful in treating psoriasis.
  • the skin related diseases include: dermatomycosis, scleroderma, epidermolysis bullosa, eczema and systemic lupus erythematous affecting skin.
  • Some other skin diseases such as hives, acneiform eruptions, autoinflammatory diseases (Blau syndrome, Majeed syndrome, Muckle-Wells syndrome), chronic blistering diseases, skin mucus diseases, inflammation of skin appendages, diseases of alteration in pigmentation, drug-induced skin diseases, eosinophilic cutaneous conditions, bacterial or viral or fungal or parasite skin infections, lichen planus, lymphoid-related cutaneous conditions, monocyte-and macrophage-related cutaneous inflammation, reactive neutrophilic cutaneous condition, utricaria and other skin inflammation of unknown origin could also treated using topical pharmaceutical composition of compound of formula (la).
  • a pharmaceutically acceptable solution is obtained from the above ingredients, when the preparation process is carried out in the following steps: I. Compound of formula (la) is dispersed in a part of Purified water under stirring.
  • step IV Glycerin is added to solution of step III and mixed under stirring.
  • a pharmaceutically acceptable gel is obtained from the above ingredients, when the preparation process is carried out in the following steps:
  • step IV Glycerin is added to solution of step III and mixed under stirring.
  • step V Hydroxyethyl cellulose is slowly added to solution of step IV under constant stirring and mixed till clear homogenous gel is obtained.
  • a pharmaceutically acceptable lotion is obtained from the above ingredients, when the preparation process is carried out in the following steps:
  • step IV Glycerin is added to solution of step III and mixed under stirring.
  • V Hydroxyethyl cellulose is slowly added to solution of step IV under constant stirring and mixed till clear homogenous lotion is obtained.
  • a pharmaceutically acceptable cream is obtained from the above ingredients, when the preparation process is carried out in the following steps:
  • Step IV Solution of Step IV is heated to 70°C and maintained at same temperature.
  • step VI Methyl paraben and Propyl paraben are added to solution of step VI and stirred till completely dissolved.
  • Step VII Solution of Step VII added to aqueous solution of step V under stirring at 70°C and mixed for 10 min.
  • Step VIII Mixture of Step VIII is cooled to room temperature along with constant stirring.
  • a pharmaceutically acceptable ointment is obtained from the above ingredients, when the preparation process is carried out in the following steps:
  • Polyethylene glycol 400 is heated at 75°C and maintained at same temperature.
  • step II Compound of formula (la) is dissolved in step I under stirring.
  • Polyethylene glycol 6000 is melted at 75°C and added to solution from solution of Step II under constant stirring at 75°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique topique d'inhibiteurs de HIF prolyl hydroxylase appropriés. De préférence, la présente invention concerne la composition pharmaceutique topique du composé de formule (Ia). L'invention concerne une composition pharmaceutique topique comprenant un composé de formule (Ia) ou ses sels pharmaceutiquement acceptables et des excipients pharmaceutiquement acceptables appropriés. Cette composition est utile pour le traitement de troubles cutanés.
PCT/IB2021/058243 2021-05-14 2021-09-10 Composition pharmaceutique topique d'inhibiteurs de hif prolyl hydroxylase Ceased WO2022238745A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202121021777 2021-05-14
IN202121021777 2021-05-14

Publications (1)

Publication Number Publication Date
WO2022238745A1 true WO2022238745A1 (fr) 2022-11-17

Family

ID=84028044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/058243 Ceased WO2022238745A1 (fr) 2021-05-14 2021-09-10 Composition pharmaceutique topique d'inhibiteurs de hif prolyl hydroxylase

Country Status (2)

Country Link
TW (1) TW202243676A (fr)
WO (1) WO2022238745A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598210B2 (en) * 2006-06-26 2013-12-03 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
WO2014102818A1 (fr) * 2012-12-24 2014-07-03 Cadila Healthcare Limited Dérivés inédits de quinolone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598210B2 (en) * 2006-06-26 2013-12-03 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
WO2014102818A1 (fr) * 2012-12-24 2014-07-03 Cadila Healthcare Limited Dérivés inédits de quinolone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARIO C. MANRESA ET AL.: "Pharmacologic inhibition of hypoxiainducible factor (HIF)-hydroxylases ameliorates allergic contact dermatitis", ALLERGY, vol. 74, no. 4, 12 December 2018 (2018-12-12), pages 753 - 766, XP071463729, DOI: 10.1111/all.13655 *

Also Published As

Publication number Publication date
TW202243676A (zh) 2022-11-16

Similar Documents

Publication Publication Date Title
JP5345937B2 (ja) 抗真菌組成物
US20160090600A1 (en) Composition for external application comprising transcription factor decoy as active ingredient
JP7779642B2 (ja) ロキソプロフェン配合皮膚用外用剤
JP2012524814A (ja) １，２，４−チアジアゾール誘導体の安定的な局所組成物
KR102317158B1 (ko) 항미생물 화합물, 조성물, 및 그의 용도
JP2019151645A (ja) 局所投与用薬学的組成物
JP4690672B2 (ja) 乳剤性皮膚外用剤
JPH0463852B2 (fr)
JP7150308B2 (ja) 皮膚外用組成物
WO2022238745A1 (fr) Composition pharmaceutique topique d'inhibiteurs de hif prolyl hydroxylase
JPWO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
JPH039089B2 (fr)
AU2017308830A1 (en) Pharmaceutical formulations and their use
JPH03173816A (ja) アムスロシン外用剤
JP4686144B2 (ja) 油脂性軟膏剤
JP7001356B2 (ja) 皮膚色素沈着抑制剤
WO2016157112A1 (fr) Compositions de pulvérisation topiques de furoate de mométasone
US20230241044A1 (en) Treatment for psoriasis and skin inflammatory diseases
WO1992019271A1 (fr) Composition facilitant l'administration et l'absorption percutanees, et preparation externe pour l'administration percutanee
WO2021099901A1 (fr) Composition pharmaceutique topique stable
US20210038570A1 (en) Compositions and methods for treating cutaneous fibrosis
US20230000945A1 (en) Topical pharmaceutical formulations of a cyclic depsipeptide
JPH0242812B2 (fr)
JP2024539703A (ja) デュークラバシチニブの局所製剤
JPS585885B2 (ja) 新規薬用軟膏

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21941772

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202327077421

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21941772

Country of ref document: EP

Kind code of ref document: A1